| PTCT Stock | | | USD 42.89 0.93 2.22% |
EVP
Dr. Neil Almstead, Ph.D. is Chief Technical Operations Officer of PTC Therapeutics Inc., since December 2018. Dr. Almstead was employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter Gamble Company, a publicly traded consumer products company. Dr. Almstead has coauthored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders, oncology and inflammatory diseases since 2018.
| Age | 57 |
| Tenure | 6 years |
| Address | 100 Corporate Court, South Plainfield, NJ, United States, 07080 |
| Phone | 908 222 7000 |
| Web | https://www.ptcbio.com |
Almstead received a B.S. from Clarkson University and a Ph.D. in Organic Chemistry from the University of Illinois at UrbanaChampaign.
PTC Therapeutics Management Efficiency
The company has return on total asset
(ROA) of
(0.0515) % which means that it has lost $0.0515 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(77.4012) %, meaning that it created substantial loss on money invested by shareholders. PTC Therapeutics' management efficiency ratios could be used to measure how well PTC Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Equity is likely to gain to 0.80 in 2024, whereas
Return On Tangible Assets are likely to drop
(0.46) in 2024. At this time, PTC Therapeutics'
Total Current Liabilities is comparatively stable compared to the past year.
Non Current Liabilities Total is likely to gain to about 2.2
B in 2024, whereas
Liabilities And Stockholders Equity is likely to drop slightly above 1
B in 2024.
PTC Therapeutics currently holds 2.23
B in liabilities. PTC Therapeutics has a current ratio of 1.21, suggesting that it
may have difficulties to pay its financial obligations when due. Note, when we think about PTC Therapeutics' use of debt, we should always consider it together with its cash and equity.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. Ptc Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1167 people. PTC Therapeutics (PTCT) is traded on NASDAQ Exchange in USA. It is located in 100 Corporate Court, South Plainfield, NJ, United States, 07080 and employs 988 people. PTC Therapeutics is listed under Biotechnology category by Fama And French industry classification.
Management Performance
PTC Therapeutics Leadership Team
Elected by the shareholders, the PTC Therapeutics' board of directors comprises two types of representatives: PTC Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PTC. The board's role is to monitor PTC Therapeutics' management team and ensure that shareholders' interests are well served. PTC Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PTC Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christine Utter, Principal Financial Officer, Principal Accounting Officer, Treasurer | |
| Christine CPA, Chief VP | |
| Lee MD, Executive Officer | |
| Ellen Welch, Chief Officer | |
| FACS FACS, Chief Officer | |
| Mark Boulding, Chief Legal Officer and Executive VP | |
| Stuart Peltz, Co-Founder, CEO and Executive Director | |
| Alex Kane, Investor Officer | |
| Mark JD, Executive Officer | |
| Linda Carter, Senior Officer | |
| Eric Pauwels, Chief Officer | |
| Emily Hill, Principal Financial Officer, Treasurer | |
| FACS MD, CEO Director | |
| Neil Almstead, Executive VP of Research, Pharmaceutical Operations and Technology | |
| Dawn Svoronos, Director | |
| Hege SollieZetlmayer, Senior Resources | |
| Pierre MS, Chief Officer | |
| Jane Baj, Vice Communications | |
| John Baird, Chief CEO | |
| Allan Jacobson, Co-Founder, Chairman of Scientific Advisory Board, Director and Member of Nominating and Corporate Governance Committee | |
PTC Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PTC Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for PTC Stock Analysis
When running PTC Therapeutics' price analysis, check to
measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to
predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.